« Back

Sarepta Therapeutics to Announce First Quarter 2013 Financial Results and Corporate Update on May 9, 2013

04/26/13 4:05 PM EDT

CAMBRIDGE, MA -- (Marketwired) -- 04/26/13 -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will report first quarter financial results before the NASDAQ Global Market opens on Thursday, May 9, 2013. Subsequently, at 8:00 a.m., Eastern Time (5:00 a.m., Pacific Time), Chris Garabedian, Sarepta's President and CEO, will host a conference call to discuss first quarter financial results and to provide a corporate update.

The conference call may be accessed by dialing 800.446.2782 for domestic callers and 847.413.3235 for international callers. The passcode for the call is 34783365. Please specify to the operator that you would like to join the "Sarepta First Quarter Earnings Call." The conference call will be webcast live under the investor relations section of Sarepta's website at www.sareptatherapeutics.com and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sareptatherapeutics.com.

Sarepta Investor Contact:
Erin Cox
857.242.3714

Sarepta Media Contact:
Jim Baker
857.242.3710

Source: Sarepta Therapeutics, Inc.

 

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.